Last reviewed · How we verify
Intensive statin treatment
At a glance
| Generic name | Intensive statin treatment |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Very Early PCSK9 Inhibition for Acute Myocardial Infarction (NA)
- ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) (PHASE2)
- Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management (NA)
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2) (NA)
- Effects of Short-term Intensive Statin Therapy on Lipid Levels
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (PHASE3)
- Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: